Sienna reagent and cancer biomarker registered with FDA
29 May, 2014The US FDA has registered the lead product of Melbourne-based biotech company Sienna Cancer Diagnostics - the antibody SCD-A7.
Novogen to test SBPs in prostate cancer
27 May, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has identified a number of super-benzopyran (SBP) compounds with a potent effect against prostate cancer cells in vitro, and aims to trial the lead candidate in 2015.
Prima's US patent for CVac allowed
26 May, 2014 by Dylan Bushell-EmblingThe US patent office has granted Prima BioMed a Notice of Allowance covering a patent application protecting cancer treatment candidate CVac.
IST raising $5m for cancer trial, ASX listing
21 May, 2014 by Dylan Bushell-EmblingImmune System Therapeutics (IST) has announced plans to place up to $5m in new shares, to raise funds for a phase IIb multiple myeloma trial and an ASX listing in the third quarter.
No link between vaccinations and autism
21 May, 2014A comprehensive systematic review of childhood vaccinations has found no evidence of a link to the development of autism or autism spectrum disorders.
Budget delivers a mixed bag for science
16 May, 2014 by Susan WilliamsonThe federal government's first Budget delivers a mixed outcome for science, research and innovation.
Scientific congress for the therapeutics sector
16 May, 2014If you are a professional working in the therapeutics sector, don't miss the 2014 ARCS Scientific Congress to be held in Sydney at the beginning of June.
Virax names new managing director
15 May, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has announced that former Arana Therapeutics executive Dr Rob Crombie will join the company as managing director in mid-June.
Prana adds movement disorder expert to board
14 May, 2014 by Dylan Bushell-EmblingNeurodegenerative disease expert professor Ira Shoulson has joined the Prana Biotechnology (ASX:PBT) board to help the company develop PBT2 as a treatment for Huntington disease.
Prima gets FDA fast-track status for CVac
09 May, 2014 by Dylan Bushell-EmblingShares in Prima BioMed grew 30% after the company revealed it has won fast-track designation in the US for CVac in platinum-sensitive epithelial ovarian cancer in second remission.
Awards for research excellence open
09 May, 2014Nominations are open for the annual Research Australia Awards and the 2014 GlaxoSmithKline Award for Research Excellence.
Aussie scientists develop blood test for bowel cancer
08 May, 2014 by Dylan Bushell-EmblingClinical Genomics and CSIRO have developed a DNA blood test for bowel cancer that has a detection rate of 65%, or 73% for cancers at stage II or higher.
Virax options biomarker for cancer treatment
06 May, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VLA) has optioned a technology to identify patients most likely to benefit from GGTI-2418, a cancer treatment candidate it plans to acquire with the purchase of Pathway Oncology.
Stem cells repair injured heart
05 May, 2014Researchers have successfully used embryonic stem cell-derived heart muscle cells to repair injured primate hearts.
Biomedical engineering alliance
02 May, 2014A biomedical engineering alliance strengthens the partnership between the University of Sydney and Shanghai Jiaotong University.
